Hungarian Medical Journal
Volume/Issue:
Volume 2: Issue 2
The Role of Antibody-Mediated Cellular Cytotoxicity (ADCC) in the Mechanism Underlying the Action of Trastuzumab
Author:
Márk Barok Faculty of Medicine, University of Debrecen, Medical and Health Science Center Department of Biophysics and Cell Biology Nagyerdei krt. 98 H-4012 Debrecen Hungary

Search for other papers by Márk Barok in
Current site
Google Scholar
PubMed Close
Pages:
317–328
Online Publication Date:
13 Jun 2008
Publication Date:
01 Jun 2008
Article Category:
Research Article
DOI:
https://doi.org/10.1556/hmj.2.2008.2.18
Restricted access

  • Barok, M., Isola, J., Pályi-Krekk, Zs. et al.: Trastuzumab causes ADCC-mediated growth-inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther., 2007, 6 , 2065–2072. IF: 5,131.

    Pályi-Krekk Zs. , 'Trastuzumab causes ADCC-mediated growth-inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance ' (2007 ) 6 Mol. Cancer Ther. : 2065 -2072 .

    • Search Google Scholar

  • Barok, M., Balázs, M., Nagy, P. et al.: Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett., 2008, 260 , 198–208. IF: 3.277.

    Nagy P. , 'Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor ' (2008 ) 260 Cancer Lett. : 198 -208 .

    • Search Google Scholar

  • Pályi-Krekk, Zs., Barok, M., Isola, J. et al.: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalization in trastuzumab resistant breast cancer. Eur. J. Cancer, 2007, 43 , 2423–2433. IF: 4,167.

    Isola J. , 'Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalization in trastuzumab resistant breast cancer ' (2007 ) 43 Eur. J. Cancer : 2423 -2433 .

    • Search Google Scholar

  • Friedländer, E., Barok, M., Szöllősi, J. et al.: ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol. Lett., 2008, 116 , 126–140. IF: 2,352.

    Szöllősi J. , 'ErbB-directed immunotherapy: antibodies in current practice and promising new agents ' (2008 ) 116 Immunol. Lett. : 126 -140 .

    • Search Google Scholar

  • Pályi-Krekk, Zs., Barok, M., Kovács, T. et al.: EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett., 2008, 263 , 231–42. IF: 3.277.

    Kovács T. , 'EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44 ' (2008 ) 263 Cancer Lett. : 231 -42 .

    • Search Google Scholar

  • Rákosy, Zs., Vizkeleti, L., Ecsedi, S. et al.: EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int. J. Cancer, 2007, 121 , 1729–37. IF: 4,693.

    Ecsedi S. , 'EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis ' (2007 ) 121 Int. J. Cancer : 1729 -37 .

    • Search Google Scholar

  • Barok M., Balázs M., Lázár V. et al.: Characterization of a trastuzumab resistant novel breast cancer cell line by CGH and FISH. Manuscript .

  • Collapse
  • Expand
Cover Hungarian Medical Journal
Hungarian Medical Journal
Print ISSN:
1788-6139
Online ISSN:
1789-0403

Hungarian Medical Journal
Language English
Size  
Year of
Foundation		 2007
Publication
Programme		 ceased
Volumes
per Year		  
Issues
per Year		  
Publisher Akadémiai Kiadó
Publisher's
Address		 H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher		 Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2024 2 0 0
May 2024 1 0 0
Jun 2024 5 0 0
Jul 2024 5 0 0
Aug 2024 10 0 0
Sep 2024 5 0 0
Oct 2024 2 0 0